13F Holdings
中文EN

CERS CERUS CORP

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1020214 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY54.2%
TTM EPS YoY50.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-1.0%
Net margin-2.9%
FCF margin0.2%
EBITDA margin-0.3%

Returns

ROE-10.7%
ROA-3.5%
ROIC (approx.)-3.8%
Asset turnover1.21x

Leverage & solvency

Liabilities / assets62.7%
Debt / equity0.00x
Current ratio1.96x
Interest coverage-0.36x

Cash quality & payout

Operating cash flow / net income-0.48x
Accruals ratio-5.1%
Payout ratio—
Capex / revenue1.2%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$233.80M$201.32M$186.80M$188.31M$159.52M
R&D expense$67.72M$58.91M$67.64M$64.11M$63.69M
SG&A expense$80.91M$75.89M$75.52M$83.33M$81.29M
Operating income-$8.68M-$14.22M-$30.05M-$34.08M-$48.94M
Interest expense$8.34M$8.88M$8.39M$5.83M$4.92M
Pretax income-$15.28M-$20.76M-$37.32M-$42.34M-$54.06M
Income tax$354,000$205,000$325,000$488,000$319,000
Net income-$15.63M-$20.92M-$37.49M-$42.78M-$54.37M
EBITDA-$7.25M-$12.37M-$27.45M-$31.10M-$45.79M
EPS (basic)-0.08-0.11-0.21-0.24-0.32
EPS (diluted)-0.08-0.11-0.21-0.24-0.32
Weighted avg. shares (diluted)190.59M184.56M180.27M176.54M171.28M
Balance sheet
Cash & equivalents$19.96M$21.36M$13.36M$37.36M$51.04M
Short-term investments$62.92M$60.19M$54.20M$66.57M$80.60M
Receivables$30.37M$29.78M$35.50M$34.43M$25.13M
Inventory$56.10M$38.15M$39.87M$29.00M$26.79M
Current assets$174.38M$152.02M$144.44M$170.14M$187.10M
PP&E, net$9.20M$7.15M$8.64M$10.97M$12.21M
Goodwill$1.32M$1.32M$1.32M$1.32M$1.32M
Total assets$221.86M$200.92M$197.75M$218.09M$237.50M
Current liabilities$100.80M$63.61M$67.52M$117.06M$78.56M
Total liabilities$156.89M$144.02M$144.30M$149.53M$151.88M
Shareholders' equity$64.22M$56.15M$52.65M$67.61M$84.62M
Shares outstanding192.14M185.77M181.25M177.58M173.67M
Cash flow statement
Operating cash flow$4.84M$11.36M-$43.17M-$25.61M-$33.92M
Capital expenditure$3.73M$2.84M$4.60M$2.00M$910,000
Free cash flow$1.11M$8.52M-$47.77M-$27.61M-$34.83M
Investing cash flow-$6.17M-$8.13M$8.62M$8.46M$12.69M
Financing cash flow$231,000$4.96M$10.67M$4.19M$34.29M
Depreciation & amortization$1.43M$1.85M$2.60M$2.98M$3.15M
Stock-based compensation$22.87M$22.87M$20.27M$24.46M$23.57M

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.